NEWS & VIEWS

Global private equity and venture capital news and research

Swift part-exit for Longitude as Esperion eyes IPO weeks after investment $

12 Jun 2013

Venture investors in biopharmaceutical business Esperion Therapeutics are preparing to sell down their stakes through an IPO just weeks after the company completed a $33m preferred financing round.

Sorry, you have reached your quota of 1 free article a week or you are attempting to read a Premium story. To read more, simply sign-up to our daily newsletter.


Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2015